Liliana Soroceanu, M.D., Ph.D., Scientist

California Pacific CURRENTS: The online journal of CPMC Research Institute

Uncovering the role of human cytomegalovirus in glioblastoma pathogenesis, and developing novel therapies for glioblastoma
  • Id-1 knockdown in primary human glioblastomas

    Id-1 knockdown in primary human glioblastomas (GBM) reduces neurosphere growth and Sox2 levels.

    A, primary GBM cells were processed for Id-1 immunofluorescence (left) and double immunofluorescence Id-1/Sox2 (right). Propidium iodide was used to counterstain cell nuclei. Bar, 100 µm.

    B, primary GBM cells were treated with control scrambled (ctl) or Id-1 siRNA (smart pool of 4 targeting oligonucleotides), and cell lysates were used to hybridize with a stem cell antibody array. The spots corresponding to Sox2 (1), Oct-3/4 (2), and Nanog (3) are indicated.

    C, a portion of the cell lysates was used to confirm Id-1 knockdown in GBM #1 and downregulation of Sox2, Oct-3/4, Nanog, Snail, and p-FAK levels by Western blot analysis.

    D, primary GBM cells treated with control (ctl) or Id-1 siRNA were observed in a neurosphere formation assay. Microphotographs were captured 120 hours following initial cell plating. Bar, 100 µm.

    Source: Soroceanu L, et al. Cancer Res 2013;73:1559-69. (Adapted from Figure 4)

+

Research Overview

  • Dr. Soroceanu’s earlier research in collaboration with Dr. Charles Cobbs was aimed at determining the role of human cytomegalovirus (CMV) in tumorigenesis and understanding its oncomodulatory effects. Ongoing investigations in the Soroceanu lab will further explore CMV and its actions in promoting the immunosuppressive environment of brain tumors, and determine the effects of antiviral therapies as anti-tumor agents for glioblastoma.
  • Working with fellow CPMCRI researchers Drs. Pierre Desprez and Sean McAllister, Dr. Soroceanu is studying the inhibition and down-regulation of the protein Id-1 in brain tumor cells by cannabinoid compounds including cannabidiol (CBD). She is also determining the efficacy of CBD and related compounds in sensitizing tumors to frontline therapeutics (e.g., chemotherapy).
  • With researchers in the Kashani lab at CPMCRI, Dr. Soroceanu is investigating the mechanisms by which PHIP enhances the aggressiveness of cancer and determining whether inhibiting the protein will alter the aggressive behaviors of gliomas in vivo.

Training

Dr. Soroceanu received her M.D. from the School of Medicine at the University of Iasi, Romania, and her Ph.D. in neurobiology from the University of Alabama. Before joining CPMCRI in 2006, she completed post-doctoral work in neuro-oncology at Genentech.


 

Publication Search

Publications

Cobbs C, Khan S, Matlaf L, McAllister S, Zider A, Yount G, Rahlin K, Harkins L, Bezrookove V, Singer E, Soroceanu L, HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and invasiveness via PDGFR-alpha activation. Oncotarget

Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS, Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res

Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, Kawamura R, Pakdel A, Fukuyo Y, Nguyen D, Khan S, Arauz R, Yount GL, Moore DH, Desprez PY, McAllister SD, Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res

Akhavan A, Griffith OL, Soroceanu L, Leonoudakis D, Luciani-Torres MG, Daemen A, Gray JW, Muschler JL, Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes. Cancer Res

Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS, HCMV and Gliomas Symposium, Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol

VIEW ALL
Liliana Soroceanu, M.D., Ph.D., Scientist
Primary Research Interests
  • Role of cytomegalovirus in the development of malignant gliomas
  • Anti-viral therapy for glioblastoma
  • Cannabinoids as antineoplastic agents
  • The biology of glioma stem cells
  • Targeting therapeutic resistance in glioma using non-toxic ROS modulators
     

Lab Members

Estefania Fiallos, B.Sc.
Research Associate
Jonathon Judkins, B.Sc.
Research Associate
Eric Singer, B.Sc.
Research Associate